Cataract incision size is just right thanks to new technology

Article

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Now that the device has been used as part of clinical trials in a number of hospitals it is being sold to NHS trusts in the UK for £70,000 (around €92,000). The machine guides surgeons to make the right incisions, and the clouded lens is broken up using ultrasound before it is extracted. A new folded lens is injected into the space, where it is unfurled.

"It's a very quick and efficient procedure, it's painless, [with] no stitches, and [patients] can get up and walk out straight afterwards without the need for a patch and little danger of infection," said Sheraz Daya, MD, a consultant ophthalmologist at Queen Victoria Hospital, West Sussex, UK.

Other consultants agreed with Dr Daya's assessment, although they stressed that Stellaris was not the only device capable of reducing the incision to 1.8 mm. At least two other phaco systems (Sovereign; Advanced Medical Optics & Infiniti; Alcon Laboratories) are available.

"All these technologies are a move in the right direction," said Larry Benjamin, DO, an eye surgeon at Stoke Mandeville Hospital, Buckinghamshire, UK. "Smaller cuts are better, while the mechanism keeps the eye steady. The only problem is many of the lenses on the market aren't yet small enough to fit through this kind of incision, so one side of the technology has yet to catch up with the other."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.